The Monoclonal Antibody Therapy for Severe Asthma Chart lists the four available biologic treatments in Australia: benralizumab, dupilumab, mepolizumab and omalizumab. It complements the Monoclonal antibody therapy for severe asthma information paper, and includes photography of existing medications and accompanying notes and information per treatment.
Monoclonal antibody therapies are subsidised by the Pharmaceutical Benefits Scheme (PBS) for patients in specialist care who meet strict criteria.
The new wall chart contains practice information aimed at primary health professionals to raise awareness about available biologic treatment options. Along with the updated information paper it helps health professionals navigate this complex clinical area, including key practice points, information about use in pregnancy and ongoing care of patients receiving monoclonal antibody therapy.
2025 © National Asthma Council Australia
This chart was developed independently by the National Asthma Council Australia with support from AstraZeneca Australia, GlaxoSmithKline (GSK Australia) and Sanofi.
Four monoclonal antibody therapies (benralizumab, mepolizumab, dupilumab and omalizumab) are available in Australia for the treatment of severe asthma in patients whose asthma is uncontrolled despite optimised standard treatment.
